NASDAQ:QTRXQuanterix Stock Price, Forecast & News

Quanterix's stock was trading at $18.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, QTRX shares have increased by 91.3% and is now trading at $35.41.
View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Quanterix.

4 Wall Street analysts have issued twelve-month target prices for Quanterix's shares. Their forecasts range from $35.00 to $40.00. On average, they anticipate Quanterix's stock price to reach $37.00 in the next twelve months. This suggests a possible upside of 4.5% from the stock's current price.
View analysts' price targets for Quanterix.

Press coverage about QTRX stock has trended somewhat positive this week, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Quanterix earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about Quanterix.

Quanterix saw a drop in short interest during the month of July. As of July 31st, there was short interest totaling 1,120,000 shares, a drop of 7.4% from the July 15th total of 1,210,000 shares. Based on an average trading volume of 178,700 shares, the days-to-cover ratio is currently 6.3 days. Currently, 5.8% of the shares of the stock are sold short.
View Quanterix's Current Options Chain.

Some companies that are related to Quanterix include Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT), BioNano Genomics (BNGO), Precipio (PRPO), HTG Molecular Diagnostics (HTGM), Aethlon Medical (AEMD), Scientific Industries (SCND), Pressure Biosciences (PBIO), Arrayit (ARYC) and PositiveID (PSID).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Quanterix investors own include Editas Medicine (EDIT), Akoustis Technologies (AKTS), Spero Therapeutics (SPRO), Cloudera (CLDR), Crispr Therapeutics (CRSP), Walt Disney (DIS), InVitae (NVTA), Intellia Therapeutics (NTLA), Veracyte (VCYT) and Allena Pharmaceuticals (ALNA).

(QTRX) raised $50 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 3,300,000 shares at $14.00-$16.00 per share. J.P. Morga and Leerink Partners acted as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

Quanterix trades on the NASDAQ under the ticker symbol "QTRX."

Quanterix's stock is owned by a number of retail and institutional investors. Top institutional investors include Frontier Capital Management Co. LLC (2.96%), Kornitzer Capital Management Inc. KS (0.94%), WINTON GROUP Ltd (0.32%), Moody Aldrich Partners LLC (0.29%), Cadence Capital Management LLC (0.18%) and Swiss National Bank (0.15%). Company insiders that own Quanterix stock include Amol Chaubal, David C Duffy, David R Walt, Dawn Mattoon, E Kevin Hrusovsky, Ernest Orticerio, John J Fry, John M Connolly, Joseph Driscoll, Marijn E Dekkers, Mark T Roskey and Martin D Madaus.
View institutional ownership trends for Quanterix.

QTRX stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, Kornitzer Capital Management Inc. KS, and UBS Group AG. Company insiders that have sold Quanterix company stock in the last year include Amol Chaubal, David C Duffy, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, Marijn E Dekkers, Mark T Roskey, and Martin D Madaus.
View insider buying and selling activity for Quanterix.

QTRX stock was bought by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Moody Aldrich Partners LLC, Cadence Capital Management LLC, Valmark Advisers Inc., Monarch Partners Asset Management LLC, Swiss National Bank, SG Americas Securities LLC, and Focused Wealth Management Inc. Company insiders that have bought Quanterix stock in the last two years include David R Walt, and John M Connolly.
View insider buying and selling activity for Quanterix.

Shares of QTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of QTRX stock can currently be purchased for approximately $35.41.

Quanterix has a market capitalization of $1.00 billion and generates $56.73 million in revenue each year. The company earns $-40,800,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Quanterix employs 177 workers across the globe.

The official website for Quanterix is www.quanterix.com.

Quanterix's mailing address is 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821. The company can be reached via phone at 617-301-9400.